Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

DSM - Repurchase of Shares (12 - 18 May 2017)

Royal DSM
Posted on: 19 May 17

PR Newswire

HEERLEN, Netherlands, May 19, 2017

HEERLEN, Netherlands, May 19, 2017 /PRNewswire/ --

Royal DSM, a global science-based company active in health, nutrition and materials , has repurchased 139,447 of it s own shares in the period from 12 May 201 7 up to and including 18 May 2017 at an average price of 66.6 6 . This is in accordance with the repurchase , covering existing option plans and stock dividend s , announced on 13 March 2017 . The consideration of this repurchase was 9.3 million. 

The total number of shares repurchased under this program to date is 1,611,545 shares for a total consideration of €103.4 million.

     (Logo: )

For more detailed information see the 'Daily transaction details 2.9m Share Repurchase Program announced 13 Mar 2017'.

DSM - Bright Science. Brighter Living.™ 

Royal DSM is a global science-based company active in health, nutrition and materials. By connecting its unique competences in life sciences and materials sciences DSM is driving economic prosperity, environmental progress and social advances to create sustainable value for all stakeholders simultaneously. DSM delivers innovative solutions that nourish, protect and improve performance in global markets such as food and dietary supplements, personal care, feed, medical devices, automotive, paints, electrical and electronics, life protection, alternative energy and bio-based materials. DSM and its associated companies deliver annual net sales of about €10 billion with approximately 25,000 employees. The company is listed on Euronext Amsterdam. More information can be found at

Forward-looking statements

This press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations, estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release, unless required by law. The English language version of the press release is leading.

For more information:
DSM Corporate Communications
Stephen Hufton
tel. +31(0)45-5782017        

DSM Investor Relations
Dave Huizing
tel. +31(0)45-5782864


PR Newswire

Last updated on: 19/05/2017

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.